Review of How the Endocannabinoid System Works and Its Potential for New Treatments | Research

The takeaway

The discovery of the endocannabinoid signaling system has opened possibilities for developing new treatments targeting pain, epilepsy, spasticity, eating disorders, inflammation, and potentially blood pressure, based on how endocannabinoids maintain physiological balance.

Read this if you want to understand how your body's own cannabinoid system works and why it matters for developing new medicines.

Endocannabinoid system activation can enhance or dampen neural circuits depending on their existing state

What the researchers found

This review examined the endocannabinoid signaling system, including CB1 receptors (heavily represented in the central nervous system), CB2 receptors (localized to immune cells), and their endogenous ligands anandamide and 2-arachidonoyl glycerol.

A key insight was that endocannabinoid system activation can enhance or dampen neural circuit activity depending on the circuit's existing state of activation. This suggests a fundamental role in maintaining physiological steady state, essentially acting as a biological balancing mechanism.

The therapeutic implications include potential applications for neuroprotection, certain types of pain, epilepsy, spasticity, eating disorders, inflammation, and possibly blood pressure control. Both botanical cannabis and synthetic molecules acting as agonists, antagonists, or modulators of endocannabinoid metabolism show therapeutic promise.

Why it matters

The concept of endocannabinoids as a physiological balancing system helps explain why cannabinoids can have seemingly contradictory effects in different contexts. This framework guides research into developing targeted therapeutics rather than relying on whole-plant cannabis.

The numbers in context

Two established receptor types: CB1 (CNS and other tissues) and CB2 (immune cells). Two main endogenous ligands: anandamide and 2-arachidonoyl glycerol. Therapeutic targets identified: neuroprotection, pain, epilepsy, spasticity, eating disorders, inflammation, blood pressure.

How the study worked

Narrative review examining current understanding of CB1, CB2, and other possible cannabinoid receptors, their endogenous ligands, and physiological roles. Reviewed evidence for therapeutic applications of botanical cannabis and synthetic cannabinoid molecules.

What this study cannot tell us

This is a broad overview rather than a deep dive into any single therapeutic application. Most therapeutic evidence at the time was preclinical. The review acknowledges addiction potential as a concern alongside therapeutic promise.

How to read the evidence

Narrative review of endocannabinoid system biology and therapeutic potential. Provides a strong conceptual framework but most therapeutic applications discussed were preclinical at the time.

When this study was published

Published in 2005. The endocannabinoid field has expanded enormously since then, with several therapeutic applications now in clinical use or advanced trials.

The bigger picture

Understanding the endocannabinoid system as a homeostatic regulator has become a foundational concept in cannabinoid science. This framework explains why endocannabinoid-based treatments might work differently from simple cannabis use, and why both agonists and antagonists at cannabinoid receptors could have therapeutic value.

Questions still open

Can drugs that modulate endocannabinoid metabolism provide therapeutic benefits without the psychoactive effects of direct cannabinoid receptor activation? Which therapeutic applications will translate most successfully from preclinical to clinical settings?

Common questions

What is the endocannabinoid system?

It is a signaling system in the body consisting of cannabinoid receptors (CB1 in the brain and other tissues, CB2 on immune cells) and naturally produced molecules (endocannabinoids like anandamide) that bind to them. This system helps maintain physiological balance across many body functions.

Can the endocannabinoid system be targeted for treatment without using cannabis?

Yes. Synthetic molecules that act as agonists, antagonists, or modulators of endocannabinoid metabolism are being developed. These could potentially provide therapeutic benefits while avoiding the psychoactive effects of cannabis.

Read the original research

Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Clinical neuroscience research, 5(2-4), 185-199

View on PubMed ↗

Citation

Grant, Igor; Cahn, B Rael. (2005). Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.. Clinical neuroscience research, 5(2-4), 185-199.